Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $229.90 +2.36%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.15 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.55 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber sells part of its Aurora stake in block trade - Bloomberg
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Bill Rasmussen, ESPN founder, dies at 93
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
